• Annual Report 2020

    Online Version

To our Shareholders

These are extraordinary times – for the entire world, but also for us as a company. We are looking back on a year unlike any we have experienced before. A year of huge challenges in both medical and economic terms. Challenges that to a great extent are still with us. Just how we have dealt with and will continue to deal with these challenges – the successes we have had and what we are going to do to remain successful – is what I intend to convey to you below.

Read more

Focus COVID-19

Fresenius is making important contributions to high-quality and affordable health care worldwide during the COVID-19 pandemic. In this way, we are standing by our patients – and living up to our social responsibility.

We provide here a brief overview of the implications of COVID-19 on Fresenius and our individual business segments in 2020.

Read more

Sustainability Report

We are committed to responsible and sustainable management as part of our corporate culture and day-to-day business practice. Only by doing so can we be perceived as a trustworthy and reliable partner in the health care sector.

Sustainability Report

Financial Highlights FY/20



+5% 1

FY/19: €35,409 m


0.88 ²


FY/19: €0.84


4,612 m

0% 1

FY/19: €4,688 m



Dec. 31, 2019: 294,134

Net Income 3,4

1,796 m

-3% 1

FY/19: €1,879 m

Earnings per Share 3,4


-3% 1

FY/19: €3.37

1 In constant currency
2 Proposal
3 Before special items
4 Net income attributable to shareholders of Fresenius SE & Co. KGaA

More information

Fresenius Strategy

More information
  • Fresenius Medical Care

    • 2020 financial targets achieved: 5% revenue and 12% net income growth 
    • Growth in home dialysis on track 

  • Fresenius Kabi

    • In North America fewer elective treatments, competitive pressure and temporary manufacturing issues outweighed extra demand for COVID-19 related products 
    • Europe showed strong organic sales growth primarily based on extra demand for COVID-19 related products; China with healthy organic growth 
    • Strong EBIT growth in Emerging Markets with positive development in China only partially compensates EBIT decrease in North America 

  • Fresenius Helios

    • Recovery of elective procedures in Spain
    • Financial support provided by German government
    • Acquisitions in Latin America supported growth

  • Fresenius Vamed

    • Significant COVID-19 impact in the project business related to delays, cancellations and global supply chain restraints
    • Rehabilitation business impacted by less demand for rehabilitation treatments and postponements of elective surgeries; technical service business remained robust

Group Management Report

To the Group Management Report

Financial Statements

To the Financial Statements